 Connection
Michael Harris-Love to Middle Aged
This is a "connection" page, showing publications Michael Harris-Love has written about Middle Aged.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.302 |
|
|
|
-
Oranchuk DJ, Bodkin SG, Boncella KL, Harris-Love MO. Exploring the associations between skeletal muscle echogenicity and physical function in aging adults: A systematic review with meta-analyses. J Sport Health Sci. 2024 Nov; 13(6):820-840.
Score: 0.057
-
Ma?ago MM, Seamon BA, Boncella KL, Wallin MT, Maloni H, Hoover B, Blackman MR, Harris-Love MO. Ultrasound measures of muscle morphology in people with multiple sclerosis are associated with muscle performance and functional mobility. Mult Scler Relat Disord. 2023 Jul; 75:104759.
Score: 0.053
-
Davenport TE, Benson K, Baker S, Gracey C, Rakocevic G, McElroy B, Dalakas M, Shrader JA, Harris-Love MO. Lower extremity peak force and gait kinematics in individuals with inclusion body myositis. Arthritis Care Res (Hoboken). 2015 Jan; 67(1):94-101.
Score: 0.030
-
Davenport TE, Shrader JA, McElroy B, Rakocevic G, Dalakas M, Harris-Love MO. Validity of the single limb heel raise test to predict lower extremity disablement in patients with sporadic inclusion body myositis. Disabil Rehabil. 2014; 36(26):2270-7.
Score: 0.028
-
Harris-Love MO, Shrader JA, Davenport TE, Joe G, Rakocevic G, McElroy B, Dalakas M. Are repeated single-limb heel raises and manual muscle testing associated with peak plantar-flexor force in people with inclusion body myositis? Phys Ther. 2014 Apr; 94(4):543-52.
Score: 0.028
-
Harris-Love MO, Shrader JA. Patellofemoral knee pain in an adult with radiographic osteoarthritis and human immunodeficiency virus infection. J Orthop Sports Phys Ther. 2009 Aug; 39(8):612-7.
Score: 0.021
-
Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Cintas HL, McGarvey CL, James-Newton L, Pokrovnichka A, Moini B, Cabalar I, Lovell DJ, Wesley R, Plotz PH, Miller FW, Hicks JE, Rider LG. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford). 2009 Feb; 48(2):134-9.
Score: 0.020
-
Harris-Love MO. Safety and efficacy of submaximal eccentric strength training for a subject with polymyositis. Arthritis Rheum. 2005 Jun 15; 53(3):471-4.
Score: 0.015
-
Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba ML, Myones BL, Pachman LM, Rennebohm RM, Reed AM, Miller FW. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009 Nov; 60(11):3425-35.
Score: 0.010
-
Schiffenbauer A, Garg M, Castro C, Pokrovnichka A, Joe G, Shrader J, Cabalar IV, Faghihi-Kashani S, Harris-Love MO, Plotz PH, Miller FW, Gourley M. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum. 2018 06; 47(6):858-864.
Score: 0.009
-
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013 Feb; 65(2):314-24.
Score: 0.007
-
Fern?ndez-Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO, Shrader JA, Lehky TJ, Li L, Ryder JE, Levy EW, Solomon BI, Harris-Love MO, La Pean A, Schindler AB, Chen C, Di Prospero NA, Fischbeck KH. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb; 10(2):140-7.
Score: 0.006
-
Rhodes LE, Freeman BK, Auh S, Kokkinis AD, La Pean A, Chen C, Lehky TJ, Shrader JA, Levy EW, Harris-Love M, Di Prospero NA, Fischbeck KH. Clinical features of spinal and bulbar muscular atrophy. Brain. 2009 Dec; 132(Pt 12):3242-51.
Score: 0.005
-
Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, Shrader JA, Levy EW, Dambrosia J, Kampen RL, Bruno DA, Kirk AD. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009 Jun; 132(Pt 6):1536-44.
Score: 0.005
-
Sparks S, Rakocevic G, Joe G, Manoli I, Shrader J, Harris-Love M, Sonies B, Ciccone C, Dorward H, Krasnewich D, Huizing M, Dalakas MC, Gahl WA. Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study. BMC Neurol. 2007 Jan 29; 7:3.
Score: 0.004
-
Youdas JW, Atwood AL, Harris-Love MO, Stiller TL, Egan KS, Therneau TM. Measurements of temporal aspects of gait obtained with a multimemory stopwatch in persons with gait impairments. J Orthop Sports Phys Ther. 2000 May; 30(5):279-86.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|